98%
921
2 minutes
20
Friedreich ataxia (FRDA) is the most common type of inherited ataxia. It is a neurodegenerative disorder characterized by progressive gait and limb ataxia, dysarthria, areflexia, and reduced proprioception and vibration sensation. Although a number of clinical trials have been conducted, there is currently no cure for this disease. In this article we review those clinical trials with a focus on the instruments used as endpoints to assess clinical progression, and discuss the potential benefits of integrating additional measures, including assessments from overlooked domains. We also review tools used to evaluate cognitive functions in individuals with FRDA, particularly those employing quantitative, objective, and time-based measures. We argue for the inclusion of cognitive and speech-related assessments in clinical trials, and examine the potential of developments in cognitive neuroscience and technology to address current measurement challenges and support more accurate and comprehensive evaluation of treatment effects. These innovations have the potential to complement existing approaches, enhance trial design, and advance clinical care.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12142069 | PMC |
http://dx.doi.org/10.3389/fneur.2025.1558493 | DOI Listing |
J Cell Mol Med
September 2025
Department of Pharmacy, Faculty of Health and Life Sciences, Daffodil International University, Dhaka, Bangladesh.
Ferroptosis, a controlled cell death influenced by iron-dependent lipid peroxidation, presents potential therapeutic targets for cancer treatment due to its unique molecular pathways and potential drug resistance. Natural compounds, such as polyphenols, flavonoids, terpenoids and alkaloids, can influence ferroptosis via important signalling pathways, such as Nrf2/Keap1, p53, and GPX4. These are promising for combinational therapy due to their ability to cause ferroptotic death in cancer cells, exhibit tumour-specific selectivity and reduce systemic toxicity.
View Article and Find Full Text PDFAlzheimers Dement
September 2025
School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Camperdown, Sydney, New South Wales, Australia.
Introduction: Risperidone is approved for behaviors and psychological symptoms of dementia (BPSD), despite modest efficacy and known risks. Identifying responsive symptoms, treatment modifiers, and predictors is crucial for personalized treatment.
Method: A one-stage individual participant data meta-analysis of six randomized controlled trials (risperidone: n = 1009; placebo: N = 712) was conducted.
Monash Bioeth Rev
September 2025
Department of Biochemistry, Cell and Molecular Biology, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.
This paper examines bioethical considerations of research conducted in Sub-Saharan Africa (SSA), where a notable scarcity persists in literature addressing region-specific bioethical issues. Although bioethics-related activities have encountered challenges surpassing existing protocol safeguards, emerging evidence demonstrates growing recognition of integrated scientific and ethical principles within African medical research. Maintaining research continuity in resource-limited settings necessitates bridging critical gaps between informed consent procedures and participants' actual understanding.
View Article and Find Full Text PDFTrends Pharmacol Sci
September 2025
Department of Biosciences and Bioinformatics & Suzhou Municipal Key Lab of Biomedical Sciences and Translational Immunology, School of Science, Xi'an Jiaotong-Liverpool University, Suzhou, China; Biomedical Research Center, School of Science, Engineering and Environment, University of Salford, Manch
Regulatory T cells (Tregs) play a pivotal role in maintaining immune tolerance and sustaining immunological homeostasis. Emerging evidence indicates that Treg characteristics and functional alterations can significantly contribute to the pathogenesis of autoimmune diseases including type 1 diabetes mellitus (T1DM). Notably, recent studies have established a positive correlation between diminished numbers of Tregs and the onset of T1DM.
View Article and Find Full Text PDFAnn Rheum Dis
September 2025
Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands.
Objectives: This study aims to develop recommendations on reporting baseline features and outcomes from axial spondyloarthritis (axSpA) clinical trials based on the recently updated instrument set of the Assessment of SpondyloArthritis international Society (ASAS) core outcome set (COS).
Methods: A steering group (SG) convened a workgroup (WG), consisting of 13 ASAS members including rheumatologists, methodologists, epidemiologists, and 2 Young ASAS members. Recommendations on reporting axSpA trials baseline features and outcomes were developed in 3 steps: (1) the SG identified relevant baseline features from key axSpA clinical trials and formulated a proposal on how outcomes related to the instruments in the ASAS COS should be presented.